Aardvark Therapeutics (AARD) announced that Institutional Review Board, IRB, approval has been granted in the United States for an amended protocol to its ongoing Phase 3 HERO pivotal clinical trial evaluating ARD-101 for the treatment of hyperphagia in individuals with Prader-Willi Syndrome. The amended protocol, submitted to the U.S. Food and Drug Administration, FDA, lowers the minimum age of eligibility for trial participation from 10 to 7 years old.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AARD:
- Undervalued Obesity Innovator: Justifying a Buy on Aardvark’s Dual Rare-Disease and Mainstream Metabolic Opportunity
- Aardvark Therapeutics initiated with a Buy at B. Riley
- Ten new option listings and two option delistings on January 22nd
- Aardvark Therapeutics: Clinical Momentum and 2026 Catalyst Stack Underpin Buy Rating and $26 Target
- Aardvark Therapeutics updates investor presentation on hunger therapies